On March 31, 2025, BioCardia, Inc. announced positive two-year outcomes from its Phase 3 CardiAMP-HF study, showing significant improvements in heart failure patients treated with their cell therapy compared to those on standard medication. Key results included a 47% relative risk reduction in heart death equivalents and a 10.5-point improvement in quality of life scores.